DataVXACS Applied Materials & InterfacesPaper
journal article·2019-02-20Open access

Targeted T1 Magnetic Resonance Imaging Contrast Enhancement with Extraordinarily Small CoFe2O4 Nanoparticles

Dominique Piché, Isabella Tavernaro, Jana Fleddermann, Juan G. Lozano, Aakash Varambhia, Mahon L. Maguire, Marcus Koch, Tomofumi Ukai, Armando J. Hernández Rodríguez, Lewys Jones, Frank Dillon, Israel Reyes Molina, Mai Mitzutani, Evelio R. González Dalmau, Toru Maekawa, Peter D. Nellist, Annette Kraegeloh, Nicole Grobert

ACS Applied Materials & Interfaces· Volume 11· Issue 7
Publisher pageOpen full text
Source abstract

Abstract

Extraordinarily small (2.4 nm) cobalt ferrite nanoparticles (ESCIoNs) were synthesized by a one-pot thermal decomposition approach to study their potential as magnetic resonance imaging (MRI) contrast agents. Fine size control was achieved using oleylamine alone, and annular dark-field scanning transmission electron microscopy revealed highly crystalline cubic spinel particles with atomic resolution. Ligand exchange with dimercaptosuccinic acid rendered the particles stable in physiological conditions with a hydrodynamic diameter of 12 nm. The particles displayed superparamagnetic properties and a low r2/ r1 ratio suitable for a T1 contrast agent. The particles were functionalized with bile acid, which improved biocompatibility by significant reduction of reactive oxygen species generation and is a first step toward liver-targeted T1 MRI. Our study demonstrates the potential of ESCIoNs as T1 MRI contrast agents.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

NanomaterialsBiomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanocluster Synthesis and Applications · Magnetic Properties and Synthesis of Ferrites

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Materials Department, University of Oxford, Parks Road, Oxford OX1 3PH, England

INM - Leibniz Institute for New Materials, Campus D2 2, 66123 Saarbrücken, Germany

British Heart Foundation Experimental Magnetic Resonance Unit, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, England

Bio-Nano Electronics Research Centre, Toyo University, 2100, Kujirai, Kawagoe, Saitama 350-8585, Japan

Departamento de Imágenes por Resonancia Magnética, Cuban Neurosciences Center, Street 190 e/25 and 27, Cubanacan Playa, Havana CP 11600, Cuba

Advanced Microscopy Laboratory, Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN), Dublin 2, Ireland

School of Physics, Trinity College Dublin, Dublin 2, Ireland

Department of Material Science and Engineering, Tokyo Institute of Technology, S8-25, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan

Williams Advanced Engineering, Grove, Oxfordshire, OX12 0DQ, England

Funding

Royal Society · Engineering and Physical Sciences Research Council · University of Oxford · FP7 Ideas: European Research Council · H2020 European Research Council

References (72)

Show source-provided references
1. 10.1148/radiol.1515002510.1148/radiol.15150025 ↗
2. Gadolinium-Containing Contrast Agents: Removal of Omniscan and iv Magnevist, Restrictions to the Use of Other Linear Agents. https://www.gov.uk/drug-safety-update/gadolinium-containing-contrast-agents-removal-of-omniscan-and-iv-magnevist-restrictions-to-the-use-of-other-linear-agents.
3. 10.1016/j.carj.2012.07.00310.1016/j.carj.2012.07.003 ↗
4. 10.1039/C5CS00541H10.1039/C5CS00541H ↗
5. 10.21037/qims.2017.02.0910.21037/qims.2017.02.09 ↗
6. 10.4061/2011/48934210.4061/2011/489342 ↗
7. 10.2174/15734051280067221610.2174/157340512800672216 ↗
8. 10.1021/ja203340u10.1021/ja203340u ↗
9. 10.1073/pnas.162014511410.1073/pnas.1620145114 ↗
10. 10.1039/C6RA00347H10.1039/C6RA00347H ↗
11. 10.1021/acsnano.6b0768410.1021/acsnano.6b07684 ↗
12. 10.3402/nano.v1i0.535810.3402/nano.v1i0.5358 ↗
13. 10.1371/journal.pone.016872710.1371/journal.pone.0168727 ↗
14. 10.3390/nano802006310.3390/nano8020063 ↗
15. 10.1038/srep4007510.1038/srep40075 ↗
16. 10.1021/jp905776g10.1021/jp905776g ↗
17. 10.1021/jp402302510.1021/jp4023025 ↗
18. 10.1039/C2CE25957E10.1039/C2CE25957E ↗
19. 10.2217/nnm.11.1610.2217/nnm.11.16 ↗
20. 10.1021/la303700710.1021/la3037007 ↗
21. 10.1002/anie.20046166510.1002/anie.200461665 ↗
22. 10.1016/j.jallcom.2011.05.11510.1016/j.jallcom.2011.05.115 ↗
23. 10.1021/ja038085210.1021/ja0380852 ↗
24. 10.1351/pac20067805100310.1351/pac200678051003 ↗
25. 10.1021/nl500776e10.1021/nl500776e ↗
26. 10.1039/C5NR04266F10.1039/C5NR04266F ↗
27. 10.1039/C3DT53179A10.1039/C3DT53179A ↗
28. 10.1006/jcis.1997.512510.1006/jcis.1997.5125 ↗
29. 10.1016/j.jcis.2014.09.01910.1016/j.jcis.2014.09.019 ↗
30. 10.3748/wjg.15.80410.3748/wjg.15.804 ↗
31. Kramer W. · J. Biol. Chem. · 1992 · 267 · 1859810.1016/S0021-9258(19)37003-6 ↗
32. 10.1021/acs.molpharmaceut.6b0018810.1021/acs.molpharmaceut.6b00188 ↗
33. 10.1016/j.bmcl.2008.01.04410.1016/j.bmcl.2008.01.044 ↗
34. 10.1021/jm070397i10.1021/jm070397i ↗
35. 10.2174/156802661566615050615010910.2174/1568026615666150506150109 ↗
36. 10.1021/om060791z10.1021/om060791z ↗
37. 10.1021/cm802978z10.1021/cm802978z ↗
38. 10.1186/s40679-015-0008-410.1186/s40679-015-0008-4 ↗
39. 10.1103/PhysRevB.44.1140210.1103/PhysRevB.44.11402 ↗
40. 10.1016/0304-3991(82)90213-310.1016/0304-3991(82)90213-3 ↗
41. 10.1016/j.micron.2005.12.00410.1016/j.micron.2005.12.004 ↗
42. 10.1038/ncomms615410.1038/ncomms6154 ↗
43. 10.1016/j.matchemphys.2015.07.01810.1016/j.matchemphys.2015.07.018 ↗
44. 10.1088/2053-1591/aa96e310.1088/2053-1591/aa96e3 ↗
45. 10.1016/j.nantod.2011.08.00110.1016/j.nantod.2011.08.001 ↗
46. 10.1016/j.colsurfa.2007.09.01710.1016/j.colsurfa.2007.09.017 ↗
47. 10.1186/1556-276X-8-38110.1186/1556-276X-8-381 ↗
48. 10.1039/C5NJ02441B10.1039/C5NJ02441B ↗
49. 10.1039/C3MH00106G10.1039/C3MH00106G ↗
50. Noori A. · Afr. J. Biotechnol. · 2011 · 10 · 1221
51. 10.1021/ja035474n10.1021/ja035474n ↗
52. 10.1021/jp801663410.1021/jp8016634 ↗
53. 10.1016/j.jfda.2014.01.00510.1016/j.jfda.2014.01.005 ↗
54. 10.1002/smll.20170411110.1002/smll.201704111 ↗
55. 10.1016/0378-4274(95)03532-X10.1016/0378-4274(95)03532-X ↗
56. 10.1063/1.496456310.1063/1.4964563 ↗
57. 10.1046/j.1432-1327.1998.2560016.x10.1046/j.1432-1327.1998.2560016.x ↗
58. 10.1186/1743-8977-10-3210.1186/1743-8977-10-32 ↗
59. Ghasemian Z. · Avicenna J. Med. Biotechnol. · 2015 · 7 · 64
60. 10.1039/c3ra23232h10.1039/c3ra23232h ↗
61. 10.1097/01.rli.0000184756.66360.d310.1097/01.rli.0000184756.66360.d3 ↗
62. 10.1155/2017/785928910.1155/2017/7859289 ↗
63. 10.1016/j.jmmm.2012.05.03110.1016/j.jmmm.2012.05.031 ↗
64. 10.1021/bc00008a00710.1021/bc00008a007 ↗
65. 10.1021/jm031068310.1021/jm0310683 ↗
66. 10.1016/j.bbamem.2006.04.00910.1016/j.bbamem.2006.04.009 ↗
67. 10.1002/masy.20065090910.1002/masy.200650909 ↗
68. Eriksson, P. A New Synthesis of Nanoparticles Designed for Biomedical Imaging. A Pilot Study. Dissertation, Linkoping University, 2013.
69. 10.1016/0003-9861(90)90004-I10.1016/0003-9861(90)90004-I ↗
70. 10.1002/hep.184040042710.1002/hep.1840400427 ↗
71. 10.1016/S0006-2952(02)01391-610.1016/S0006-2952(02)01391-6 ↗
72. 10.3748/wjg.15.167710.3748/wjg.15.1677 ↗